Atopic Dermatitis (AD) Treatment Market By Drug Type (Anti-Inflammatory Agents, Antihistamines, Immunomodulators, Interleukin Inhibitors, Topical Phosphodiesterase-4 (PDE-4) Inhibitors, Antiviral Agents, Antibiotics) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Atopic dermatitis, also known as atopic eczema, is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. The atopic dermatitis treatment market is rapidly growing due to factors such as the growing prevalence of AD, significant unmet needs, and promising pipeline molecules that would fuel the market's growth.

The report titled "Atopic Dermatitis (AD) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall Atopic Dermatitis (AD) treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug type and different geographical regions.

Geographically, the global AD treatment market is studied for the following regional markets:

      • North America
        • U.S.
        • Canada
      • Europe
        • Germany
        • France
        • Italy
        • U.K.
        • Russia
        • Rest of Europe
      • Asia-Pacific
        • India
        • China
        • Japan
        • Rest of Asia-Pacific
      • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
      • Middle East and Africa
        • GCC Countries
        • South Africa
        • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global AD treatment market. Pipeline analysis of AD treatment molecules and global epidemiology data have been included in the report. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global AD treatment market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global AD treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global AD treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug type, the global atopic dermatitis (AD) treatment market is segmented as follows:

      • Anti-inflammatory agents
      • Corticosteroids
      • Calcineurin Inhibitors
      • Antihistamines
      • Immunomodulators
      • Interleukin Inhibitors
      • Topical Phosphodiesterase-4 (PDE-4) Inhibitors
      • Antiviral agents
      • Antibiotics

Atopic dermatitis (AD), also known as atopic eczema, is an inflammatory disease of the skin in which the skin becomes extremely itchy and inflamed, causing redness, swelling, and vesicle formation. There is no cure for AD, but medications are used to relieve itching and prevent new outbreaks. It is studied that, currently, anti-inflammatory agents hold the largest market share in the global atopic dermatitis treatment market.

Among the considered anti-inflammatory segments, corticosteroids are a major revenue-generating segment as these are preferred as first-line treatments after the failure of skin care and moisturizers due to their effectiveness. During the forecast period, new product launches are expected to drive the AD treatment market's growth. Pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab, and tralokinumab are expected to show AD treatment market growth during the forecast period. However, adverse effects associated with medication and poor treatment compliance in some countries may negatively impact the AD treatment market's growth.

For the purpose of this study, the global atopic dermatitis (AD) treatment market is categorized into three segments:

      • North America
      • Europe
      • Asia Pacific
      • Latin America (LATAM)
      • Middle East and Africa (MEA)

Atopic dermatitis (AD) is a chronic, inflammatory disease of the skin characterized by dry, itchy skin. The prevalence of AD is approximately 15–20% in children and 1–3% in adults worldwide, and the incidence has increased by 2–3 folds during the past decade in industrialized countries. Among the considered geographical segments, North America was the major revenue-generating segment in the base year 2016. Some factors, such as the increase in the prevalence of AD, higher treatment awareness, the swift adoption of novel medications, and better reimbursement policies in healthcare systems, are the prime contributors to the dominance of the North American atopic dermatitis market. Expenditure on healthcare is highest in the United States as compared to other nations, which is another factor contributing to the growth of the AD treatment market.

According to the American Academy of Dermatology, approximately 10 to 20 percent of children in the United States develop atopic dermatitis; AD affects more than 28 million people of all ages in the United States alone. It is estimated that Asia Pacific will show the highest AD treatment market growth during the forecast period due to increasing healthcare awareness among the general patient population, developing economic conditions, a growing number of investments, and the partnering of key players with local manufacturers.

Frequently Asked Question:

The market for Atopic Dermatitis Treatment Market is expected to reach USD$ 7.66 Bn in 2025.

The Atopic Dermatitis Treatment Market is expected to see significant CAGR growth over the coming years, at 7.4%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

AbbieVie Inc.,Encore Dermatology Inc.,F. Hoffmann-La Roche AG,Glaxosmithkline plc.are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58654
Report Format:   PDF
Pages:   120
Rating:    4.7 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support